Apricitabine

Medical Advocates
Apricitabine (AVX754 SPD754)

Main Page

New and Noteworthy
USDHHS Information
Journal Abstracts, Papers, and Commentaries
Conference Reports, Abstracts and Posters

ARV Investigational Drugs

New and Noteworthy

Home Page

Last Update: December 08, 2014
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

October 2009

A WEEK-IN-REVIEW FEATURED REPORT
Comparison of the pharmacokinetics of apricitabine in the presence and absence of
ritonavir-boosted tipranavir: a phase I, open-label, controlled, single-centre study.
Cox S, Southby J, Linet O, et al Clin Drug Investig. 2009;29(11):721-8.

September 2009

A WEEK-IN-REVIEW FEATURED REPORT
Apricitabine: A Nucleoside Reverse Transcriptase Inhibitor for HIV Infection (October) (CE).
Gaffney MM, Belliveau PP, Spooner LM.
Ann Pharmacother. 2009 Sep 8.

ARV Investigational Drugs

New and Noteworthy

Home Page